Lipoprotein(a) and risk of myocardial infarction –– genetic epidemiologic evidence of causality

Author： Kamstrup Pia R.   Tybjæærg-Hansen Anne   Nordestgaard Bøørge G.  

Publisher： Informa Healthcare

ISSN： 0036-5513

Source： Scandinavian Journal of Clinical and Laboratory Investigation, Vol.71, Iss.2, 2011-04, pp. : 87-93

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A genetic advance: lipoprotein(a) in aortic stenosis

By Yanagawa Bobby   Gupta Nandini   Verma Subodh  

Clinical Lipidology, Vol. 8, Iss. 3, 2013-06 ,pp. : 307-309

Future Medicine

Access to resources Recommend Favorite

Lipoprotein(a): An Emerging Cardiovascular Risk Factor

By Lippi Giuseppe   Guidi Giancesare  

Critical Reviews in Clinical Laboratory Sciences, Vol. 40, Iss. 1, 2003-01 ,pp. : 1-42

Informa Healthcare

Access to resources Recommend Favorite

Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 24, Iss. 3, 2015-03 ,pp. : 223-227

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association of six genetic variants with myocardial infarction

By                        

International Journal of Molecular Medicine, Vol. 35, Iss. 5, 2015-01 ,pp. : 1451-1459

Spandidos Publications

Access to resources Recommend Favorite

Lipoprotein(a): epidemiology, atherogenic activity and impact on cardiovascular risk

By Phan Binh An P   Toth Peter P  

Clinical Lipidology, Vol. 8, Iss. 2, 2013-04 ,pp. : 195-203

Future Medicine

Access to resources Recommend Favorite